_aestheticprimal_ @aestheticprimal Jul 22 I've witnessed interesting reductions in LH whereas Testosterone shot up fr...
Incremental tailwind for vitamin-ingredient suppliers from renewed social attention to Vitamin K2 + Vitamin E supplementation
Linked assets
These are the assets attached to this thesis, along with direction, confidence, and outcome so far.
More levered to specialty nutrition ingredients than mega-cap diversified chemical exposure; still, the source is weak/consumer-noise driven.
BASF SE operates as a chemical company worldwide.
Large Vitamin E producer, but vitamins are a small slice of BASF and pricing is cyclical.
Nutrition/vitamins exposure makes it directionally aligned, though attribution from one social post is very low.
Supplement sell-through could improve, but impact is diluted across Costco’s total business.
Amazon.com, Inc.
Channel beneficiary if online supplement purchases rise; highly diversified so signal-to-noise is low.
Source proof
Source proof: Strong source proof | 3 extracted claims | 5 directional assets | 1 supporting author | headline-like title review
Anecdotal claim: a client reports improved nocturia/sleep continuity after taking 20mg vitamin K2 (MK-4) before bed for 4 days. No clinical data, no identifiable public-company catalyst, and unclear market relevance.
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
A social-media joke/comment about progesterone and relationship behavior; no financial, economic, or market-relevant information.
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Commentary about an unspecified substance reducing FSH and LH modestly, in a dose-dependent manner. No company, drug, catalyst, or tradable asset is identified.
Discussion about physiological effects of topical testosterone and DHT on HPG axis activity; no explicit market, company, product, or investable asset referenced.
The source only states that the user has heard “tons of strong reviews” about @JK99928789839, with no identifiable company/ticker, product, catalyst, timeframe, or tradable implication.
Non-financial social post about skincare/sun exposure increasing skin sensitivity; no market, company, or asset implications.
Supporting authors
Unlock full thesis monitoring
Create an account to track this ticker thesis across linked assets, alerts, Telegram workflows, and deeper source analysis.